CRIS Current Research Information System

GELSOMINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.806
NA - Nord America 2.534
EU - Europa 1.540
SA - Sud America 177
AF - Africa 163
Continente sconosciuto - Info sul continente non disponibili 151
OC - Oceania 4
Totale 7.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.457
CN - Cina 780
VN - Vietnam 762
SG - Singapore 627
IT - Italia 564
HK - Hong Kong 187
GB - Regno Unito 178
SE - Svezia 174
DE - Germania 153
BR - Brasile 132
IN - India 96
NL - Olanda 88
FR - Francia 85
BD - Bangladesh 84
KR - Corea 70
IE - Irlanda 56
FI - Finlandia 47
RU - Federazione Russa 46
TG - Togo 44
CA - Canada 41
CI - Costa d'Avorio 40
JP - Giappone 40
JO - Giordania 30
CH - Svizzera 28
ZA - Sudafrica 25
BG - Bulgaria 21
UA - Ucraina 20
PH - Filippine 19
BE - Belgio 16
MX - Messico 16
TH - Thailandia 15
TR - Turchia 14
ID - Indonesia 13
EC - Ecuador 12
PL - Polonia 12
DZ - Algeria 11
EE - Estonia 11
SC - Seychelles 11
VE - Venezuela 11
IQ - Iraq 10
PK - Pakistan 10
EG - Egitto 9
AR - Argentina 8
AT - Austria 8
ES - Italia 8
NG - Nigeria 8
TW - Taiwan 8
MY - Malesia 6
CO - Colombia 5
IL - Israele 5
AU - Australia 4
CL - Cile 4
CR - Costa Rica 4
HR - Croazia 4
IR - Iran 4
JM - Giamaica 4
LB - Libano 4
TN - Tunisia 4
UZ - Uzbekistan 4
KE - Kenya 3
LT - Lituania 3
NP - Nepal 3
OM - Oman 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
CZ - Repubblica Ceca 2
HN - Honduras 2
KG - Kirghizistan 2
KW - Kuwait 2
MA - Marocco 2
MK - Macedonia 2
MU - Mauritius 2
NI - Nicaragua 2
PA - Panama 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GR - Grecia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
NO - Norvegia 1
PR - Porto Rico 1
PY - Paraguay 1
RS - Serbia 1
UG - Uganda 1
Totale 7.225
Salva come PNG Salva come JPEG
Città #
Singapore 458
Ashburn 321
San Jose 200
Hong Kong 177
Shanghai 175
Ho Chi Minh City 150
Fairfield 142
Dong Ket 140
Hanoi 140
Southend 137
Hefei 133
Chandler 118
Council Bluffs 102
Bologna 96
Santa Clara 88
Houston 86
Woodbridge 82
Beijing 80
Seoul 67
Seattle 63
Los Angeles 61
Dallas 59
Princeton 56
Dublin 54
Wilmington 52
Cambridge 51
Milan 46
Lomé 44
Ann Arbor 42
Boardman 41
Abidjan 40
New York 36
Lauterbourg 35
Chicago 34
Helsinki 34
Turin 33
Amman 28
Florence 27
Tokyo 27
São Paulo 25
Da Nang 24
Bern 21
Nanjing 20
Redmond 20
Redondo Beach 20
Sofia 18
Haiphong 17
San Diego 17
Buffalo 16
Frankfurt am Main 16
Jinan 16
Brussels 15
Westminster 15
Naples 13
Bengaluru 12
Modena 12
Phoenix 12
Shenyang 12
The Dalles 12
Algiers 11
Biên Hòa 11
Falkenstein 11
Hải Dương 11
Johannesburg 11
Berlin 10
Des Moines 10
Montreal 10
Bremen 9
Can Tho 9
Guangzhou 9
Lappeenranta 9
Medford 9
Orem 9
Tianjin 9
Visakhapatnam 9
Abeokuta 8
Amsterdam 8
Bắc Giang 8
Denver 8
Kyiv 8
Nanchang 8
Warsaw 8
Bangkok 7
Bühl 7
Hangzhou 7
Jakarta 7
Kerpen 7
Mexico City 7
Ninh Bình 7
Redwood City 7
Shenzhen 7
Atlanta 6
Bari 6
Boydton 6
Charlotte 6
Ha Long 6
Hyderabad 6
London 6
Miami 6
Padova 6
Totale 4.418
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 455
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event 350
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 313
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 275
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 270
Next-generation technologies in predictive molecular pathology of lung cancers 256
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial 248
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 217
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 214
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 210
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 207
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 200
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 198
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 193
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 189
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 189
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer 188
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 185
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 183
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 181
Immune-mediated cholangitis: is it always nivolumab’s fault? 180
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 177
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 176
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 175
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 172
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 171
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study 166
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 163
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 163
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 162
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 154
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 141
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 137
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 111
Programmed death-1 inhibition and atherosclerosis: Can nivolumab vanish complicated atheromatous plaques? 99
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 81
null 75
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 60
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 57
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 34
Totale 7.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022432 0 0 0 22 59 30 20 27 46 31 122 75
2022/2023678 49 110 52 71 34 47 26 44 126 17 64 38
2023/2024422 24 25 15 19 17 57 13 189 12 22 24 5
2024/20251.099 60 123 75 49 111 59 73 33 10 130 99 277
2025/20262.974 329 330 215 211 230 163 304 102 541 256 149 144
2026/2027588 112 117 190 169 0 0 0 0 0 0 0 0
Totale 7.375